FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 

/0 Comments/in , , , , /by

 

  • On June 12, 2018 the FDA approved pembrolizumab (KeytrudaⓇ, Merck & Co. Inc.) for patients with chemotherapy-refractory recurrent or metastatic (r/m) cervical cancer and with a combined positive score (CPS)≥1 PD-L1 level expression.
You might also like
ESMO16 Nivolumab data – Download the PPT
Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K melanoma
Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC
FDA granted regular approval to olaparib in the treatment of (suspected) deleterious germline BRCA-mutated, HER2-negative MBC
Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)
Combinations: upcoming treatment strategies in metastatic renal cell carcinoma
Moxetumomab pasudotox-tdfk FDA approved for hairy cell leukaemia
Case sharing – use of avelumab in Merkel cell carcinoma
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

ASCO18 HCC PPT DownloadFDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patien...